S2E14: The Peptide Vote: What the FDA's Advisors Just Recommended
Welcome to Clearly Hormonal
(formerly Reset Recharge)
Dr. Komal Patil-Sisodia explains that headlines claiming “FDA approves peptides” are misleading: an FDA advisory committee narrowly voted to recommend adding six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax) to a compounding list, a step that is not FDA approval and still faces a formal FDA process. She notes FDA scientists opposed adding all six and that some voting members sell these peptides.
Reviewing the evidence, she explains that BPC-157 has only three small, weak human studies; TB-500 has zero human trials for the injury uses it's marketed for (while full thymosin beta-4 has some real human data); KPV has no human studies at all; MOTS-c has an unpublished Phase 1b trial and only observational, exercise-related human data; Epitalon lacks Western peer-reviewed human trials; and Semax is approved in Russia but with limited-quality stroke data.
She emphasizes that all six are synthetic despite being marketed as "natural," that marketing to midlife women is running well ahead of the evidence, that contamination and mislabeled dosing have been documented in online peptide products, that compounded drugs bypass typical FDA review, and that proven options already exist for symptoms like hot flashes, bone loss, and metabolic changes.
FDA Peptide “Approval” Isn't What You Think: What the Evidence Really Shows
By Dr. Komal Patil-Sisodia, MD | Eastside Menopause & Metabolism
Somewhere this week, a patient of mine is going to open Instagram, see a post about BPC-157 “getting FDA approved,” and text me about it before her next appointment. I want to get ahead of that text.
Here's what actually happened. Over a two-day meeting, a group of outside experts who advise the FDA — but don't get the final say — voted, barely, to recommend that six peptides be allowed on a special list. That list tells compounding pharmacies (specialty pharmacies that mix custom medications) which ingredients they're allowed to use. The six peptides are BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. A seventh one, called emideltide, got voted down because the evidence for it was especially weak.
That's the whole story. Not a new study. Not proof of safety. Not FDA approval of anything. Just a recommendation, from a committee, that still has to go through the FDA's own review process — a process that can take up to a year, if it happens at all.
Why did they vote yes without new evidence?
This is the part that should make you pause, not feel better. The FDA's own scientists spoke out against adding every single one of these peptides. Their concerns: we don't have solid studies in people, the way these products are made isn't consistent from batch to batch, and there's a real risk they could trigger unwanted immune reactions. The committee overruled them anyway. It's also worth knowing that several of the outside committee members who voted yes run clinics that sell these peptides. That doesn't automatically make their reasoning wrong — but it's context you deserve to have.
The main argument for adding these peptides wasn't “we now have good science.” It was harm reduction: people are already buying these online from overseas sellers with zero oversight, so maybe letting licensed pharmacies make them is the safer option. That's a real and understandable instinct from a doctor's perspective. But it's not the same thing as evidence that these peptides actually work, or that they're safe.
What do we actually know?
Let's look at the three peptides you're most likely to have heard of.
BPC-157 has a genuinely interesting backstory in animal studies — it seems to help tendons, muscles, nerves, and the gut heal in mice and rats. But in humans, the evidence is just three small, weak studies: one with 12 patients and no comparison group, one small study on a bladder condition, and one two-person study that only measured how the drug moves through the body. No large, well-designed human trial has ever been finished. It was tested in bigger trials for a bowel disease and for MS years ago, but those results were never published anywhere doctors can actually read and evaluate them. There's also a strange puzzle here: the drug disappears from the bloodstream in under 30 minutes, but people claim its effects last much longer than that — and nobody has a good explanation for why.
TB-500 comes from a natural substance in the body that does have real human study history — for healing wounds on the eye, on skin, and even helping the heart after a heart attack. But that research is on the full, natural version. TB-500 itself — the smaller, lab-made piece that's sold online for muscle and tendon injuries — has never actually been tested in people for those uses. On top of that, it's on the banned substance list for competitive athletes.
KPV has the thinnest track record of the three: there are no published human studies of any kind. Everything we know comes from mouse studies of bowel inflammation, where it looked genuinely promising — in one study, it saved every treated mouse from a condition that otherwise would have killed them. That's a great result in mice. It is not the same as a great result in people, and we don't yet know if it will work the same way.
The pitch aimed straight at women like you
Here's where I need to get a little more pointed, because this is the part of the story that actually made me want to record this episode. Of the six peptides on this list, one of them — MOTS-c — is already being marketed hard and specifically to women in midlife. The pitch is basically: your metabolism is slowing down, your bones are getting weaker, and this peptide can fix both. It's dressed up in the same wellness language you've probably seen for hormone therapy or supplements — “optimize,” “rebalance,” “restore.”
Here's the honest version. Out of everything in this group, MOTS-c does have the most interesting early science behind it when it comes to how the body handles blood sugar, energy, and bone — the exact things a lot of us start noticing changes in around perimenopause and menopause. That's a real, legitimate reason it's getting attention.
But here's the part the ads leave out: not one single peptide in this group — including MOTS-c — has ever been tested in a real study on women going through midlife hormone changes. Not one. Every promise you're seeing about hot flashes, weight, bone density, brain fog, or sleep is being made without a single study on someone in this exact life stage. That's not evidence-based medicine. That's a guess with good marketing behind it.
And the frustrating thing is, we don't actually need to guess. We already have real, tested options for every single symptom these peptides are being pitched for. Hormone therapy has real research behind it for hot flashes and bone protection. There are two newer, non-hormonal medications — elinzanetant and fezolinetant — built specifically to calm hot flashes and night sweats by working on a brain signal involved in temperature control. Exercise, especially strength training, has solid evidence for metabolism and bone health. And there are proven, well-studied treatments already available for bone loss, sleep problems, and brain fog when those are the main issue.
So the choice isn't “this peptide or nothing.” It's “this unproven peptide, or several options that have actually been tested on people like you.” When it's framed that way, the marketing starts to look a lot less like innovation and a lot more like a shortcut.
The part nobody's talking about: what's actually in the vial
Even if we set aside the question of whether these peptides work, there's a bigger problem: quality control. One analysis of peptide products seized from online sellers found that the amount of actual drug in each product ranged wildly — anywhere from 5% to 75% of what the label claimed. Several samples were contaminated with arsenic, at levels up to ten times higher than what's considered safe for an injectable drug. At least one sample had lead in it. This isn't a hypothetical risk — it's what's actually been found in products people are injecting into their bodies right now.
Getting these peptides from a licensed compounding pharmacy instead of the internet helps, but it doesn't solve everything. Compounded drugs skip the FDA's usual safety review process. A recent study looking at compounded versions of popular weight-loss drugs found significantly higher rates of contamination and mixing errors compared to the FDA-approved versions, along with more than double the risk of ending up in the hospital. Being on this new approved list does come with some basic safety checks — that's real, and it matters. But it still isn't the same level of tracking, reporting, and labeling that comes with a fully approved medication.
So what do I actually tell my patients?
I tell them the honest version: the early science is interesting, the human proof isn't there yet, and “legal for a pharmacy to make” does not mean “safe” or “well-studied.” If you're dealing with a tendon injury, a gut issue, or ongoing inflammation, there are usually proven treatment options we haven't tried yet — and those deserve a conversation before an unproven peptide does.
This isn't about making anyone feel silly for being curious, or for already having tried one of these. It's about making sure your decision is based on real information — not just on what your feed told you. Being on a list isn't the same as being proven safe. Not yet, and maybe not ever, without the kind of testing that should have come first.
New episode is up wherever you listen. Come for the peptide breakdown, stay for the part where I explain why a committee vote and a real clinical trial are two very different things.
Follow Dr. Komal Patil-Sisodia:@drpatilsisodia on Instagram and TikTok
This content is for educational purposes only and does not constitute personalized medical advice. Please discuss your specific health concerns with your own healthcare provider.